1-= INTU
Intuit boosts Q3 and FY06 rev & EPS forecast
BIIB
confirmed FDA advisory committee unanimously recommends reintroduction of TYSABRI);
Thomas Weisel upgrades Biogen (BIIB $45.50) to Peer Perform from Underperform following yesterday's FDA panel decision to allow Tysabri to re-enter the mkt
HSBC upgrades Biogen (BIIB $45.50) to Overweight from Neutral and raises their tgt to $68 from $51 saying the outcome of the Advisory was better than they expected suggesting their prior base case assumptions for Tysabri's return is too low
Biogen Idec: Susquehanna comments on Tysabri decision (BIIB) 45.50 : Susquehanna notes that yesterday afternoon, an FDA advisory committee voted unanimously to recommend a return to market for Tysabri as a treatment for relapsing multiple sclerosis. Firm was surprised by the panel's leniency towards widely anticipated labeling restrictions and monitoring requirements. They say there was an emphasis was placed on clinical vigilance, and they speculate whether the broader community neurologist shares such a similar viewpoint. Firm anticipates the FDA will follow the panel's recommendation and approve the drug by its PDUFA data (March 29) although there is a chance that additional time may be required to refine some the elements of the patient monitoring program. They estimate peak sales of Tysabri could approach $750 mln, however, at this point with no knowledge on the finer points of final risk mgmt plan to be implemented, they believe BIIB shares are fairly valued. They don't expect initial sales to surpass current bullish expectations (>$100 mln). Maintains Neutral.
Intuit boosts Q3 and FY06 rev & EPS forecast
BIIB
confirmed FDA advisory committee unanimously recommends reintroduction of TYSABRI);
Thomas Weisel upgrades Biogen (BIIB $45.50) to Peer Perform from Underperform following yesterday's FDA panel decision to allow Tysabri to re-enter the mkt
HSBC upgrades Biogen (BIIB $45.50) to Overweight from Neutral and raises their tgt to $68 from $51 saying the outcome of the Advisory was better than they expected suggesting their prior base case assumptions for Tysabri's return is too low
Biogen Idec: Susquehanna comments on Tysabri decision (BIIB) 45.50 : Susquehanna notes that yesterday afternoon, an FDA advisory committee voted unanimously to recommend a return to market for Tysabri as a treatment for relapsing multiple sclerosis. Firm was surprised by the panel's leniency towards widely anticipated labeling restrictions and monitoring requirements. They say there was an emphasis was placed on clinical vigilance, and they speculate whether the broader community neurologist shares such a similar viewpoint. Firm anticipates the FDA will follow the panel's recommendation and approve the drug by its PDUFA data (March 29) although there is a chance that additional time may be required to refine some the elements of the patient monitoring program. They estimate peak sales of Tysabri could approach $750 mln, however, at this point with no knowledge on the finer points of final risk mgmt plan to be implemented, they believe BIIB shares are fairly valued. They don't expect initial sales to surpass current bullish expectations (>$100 mln). Maintains Neutral.
راح اتطمش عليه بس 